MINOXIDIL EXTRA STRENGTH (FOR MEN)
Clinical safety rating
safeOther antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
Minoxidil is a potassium channel opener that causes direct vasodilation of peripheral arterioles. It increases blood flow to hair follicles and prolongs the anagen (growth) phase of hair follicles.
| Metabolism | Primarily metabolized by glucuronidation via UGT1A1 and UGT1A3 enzymes; minor metabolites include minoxidil sulfate, which is active. |
| Excretion | Primarily renal (approximately 95% as parent drug and metabolites). Biliary/fecal excretion is minimal (less than 5%). |
| Half-life | Terminal elimination half-life is approximately 4.2 hours in patients with normal renal function. However, the pharmacodynamic half-life (duration of antihypertensive effect) is about 24 hours, allowing once-daily dosing. |
| Protein binding | About 20% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | Approximately 3-4 L/kg, indicating extensive distribution into tissues. |
| Bioavailability | Oral: Approximately 90% absorbed, but bioavailability is around 50% due to first-pass metabolism. Topical: Systemic absorption is minimal (approximately 1.4-5% of applied dose). |
| Onset of Action | Topical application: Onset of hair regrowth is usually within 3-4 months of twice-daily application. Oral administration: Onset of antihypertensive effect occurs within 30 minutes, with peak effect at 2-3 hours. |
| Duration of Action | Topical: Duration of effect on hair growth requires continuous application; discontinuation leads to reversal of effect within 3-4 months. Oral: Antihypertensive effect persists for approximately 24 hours with once-daily dosing. |
| Molecular Weight | 209.25 |
Topical: 1 mL of 5% solution (50 mg) applied to the scalp twice daily. Maximum daily dose: 2 mL (100 mg).
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for topical minoxidil. For oral minoxidil (off-label for hypertension): GFR 10-50 mL/min: reduce dose by 50%; GFR <10 mL/min: use with caution, reduce dose by 75%. |
| Liver impairment | No specific guidelines for topical minoxidil. For oral minoxidil: Child-Pugh Class A: no adjustment; Class B: reduce dose by 50%; Class C: avoid use or reduce dose by 75%. |
| Pediatric use | Not recommended for use in children under 18 years for androgenetic alopecia. Safety and efficacy not established. |
| Geriatric use | No specific dose adjustment required for topical use. Monitor for orthostatic hypotension or fluid retention with oral use. Start at lower end of dosing range if using oral minoxidil. |
| 1st trimester | Contraindicated due to teratogenicity concerns. |
| 2nd trimester | Avoid; use only if benefit outweighs risk, close monitoring. |
| 3rd trimester | Avoid; risk of fetal hypotension/hypertrichosis. |
Clinical note
Other antihypertensive drugs can have additive effects Can cause pericardial effusion and hypertrichosis.
| FDA category | Animal |
| Placental transfer | Crosses placenta; documented in animal studies and human case reports. |
| Breastfeeding | Excreted in breast milk; use caution, monitor infant for hypotension and hypertrichosis. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Minoxidil is pregnancy category C. First trimester: Animal studies show fetal abnormalities (skeletal, cardiovascular) at high doses; no adequate human studies. Second/third trimester: Possible fetal hypotension, hypertrichosis, and perinatal complications. Avoid use in pregnant women unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, heart rate, fluid balance (weight, edema), electrolytes. Fetal monitoring: growth, amniotic fluid index, Doppler studies. Assess for fetal tachycardia or hypotension via fetal heart rate monitoring. |
| Fertility Effects | No known adverse effects on human fertility. Animal studies show no impairment of fertility at clinically relevant doses. |
■ FDA Black Box Warning
None
| Common Effects | androgenetic alopecia |
| Serious Effects |
Hypersensitivity to minoxidilPheochromocytomaConcomitant use with vasopressors (e.g., dobutamine, norepinephrine)
| Precautions | Cardiovascular effects: tachycardia, fluid retention, pericardial effusion (rarely) – risk increases with systemic absorption; avoid use in patients with pheochromocytoma or hypertensive crisis, Hypotension: can occur if applied to broken skin or excessive application, Dermatologic: contact dermatitis, scalp irritation, unwanted facial hair growth (hypertrichosis), Cardiac: avoid in patients with known coronary artery disease or arrhythmias |
| Food/Dietary | No significant food interactions. Avoid excessive alcohol intake as it may worsen orthostatic hypotension if systemic absorption occurs. |
| Clinical Pearls | Minoxidil extra strength (5%) is a topical vasodilator used for androgenetic alopecia. Onset of hair regrowth typically requires 4-6 months of twice-daily application. Initial shedding of telogen hairs may occur in the first 2-6 weeks due to synchronization of hair cycle. Use in patients with cardiovascular disease or those on antihypertensives may theoretically cause systemic effects but is rare at topical doses. Avoid concomitant use with other topical agents that may irritate scalp. Discontinue if no response after 12 months. |
| Patient Advice | Apply 1 mL to dry scalp twice daily, spreading evenly over affected areas. · Wash hands thoroughly after application to avoid unwanted hair growth. · Initial hair shedding is normal and indicates drug is working; do not stop. · Visible results may take 4-6 months; treatment is lifelong to maintain benefits. · Avoid contact with eyes, mouth, and broken skin; if contact occurs, rinse with water. · Do not use more than directed; systemic side effects are rare but include dizziness and rapid heartbeat. |
Loading safety data…